PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Published Date: 13 May 2026

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

Read Full News

Latest News

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Breast Density Laws Fall Short Raising Additional Screening

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Todays Updates

Dupilumab Improves Allergic Fungal Rhinosinusitis Outcomes

Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Fecal Transplant Raises Peanut Tolerance

Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.

Dupilumab Shows Long-Term Benefits in CRSwNP

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.

Childhood Lupus: High Disease Activity Persists in Adulthood

Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.

First Dust Mite Immunotherapy Cleared for Scotland

Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.

Todays Updates

Dupilumab Improves Allergic Fungal Rhinosinusitis Outcomes

Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Fecal Transplant Raises Peanut Tolerance

Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.

Dupilumab Shows Long-Term Benefits in CRSwNP

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.

Childhood Lupus: High Disease Activity Persists in Adulthood

Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.

First Dust Mite Immunotherapy Cleared for Scotland

Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.

Latest News

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

News All Time

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Recommended News For You

For relapsed or resistant DLBCL, odronextamab produced positive results.

Cancer during young adulthood carries long-term mental toll, study finds

Breast cancer: A new target to eliminate dormant cells before they wake

Gene therapies for BCG-unresponsive bladder cancer have high response rates.

Millions of men could benefit from faster scan to diagnose prostate cancer

Nasal therapeutic HPV vaccine could prevent cervical cancer

A study on lung cancer provides additional proof of the value of screening.

Recommended Articles For You

Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer 

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients 

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

2.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

3.

improvements in the treatment of prostate cancer resistant to chemotherapy.

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Canadian Group Calls for Earlier Colorectal Cancer Screening

1.

Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment

2.

The Pros and Cons of Steroid Therapy for ITP

3.

The Risk Factors of Venous Thromboembolism and How to Lower Your Chances 

4.

Uncovering the Mystery of the Sessile Serrated Adenoma

5.

Understanding Sideroblastic Anemia and its Symptoms 

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

1.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

3.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

4.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

5.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot